Search Results for "v"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for v. Results 211 to 220 of 220 total matches.

Antiviral Drugs for Seasonal Influenza for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
:ofab138. 27. V Ehrenstein et al. Oseltamivir in pregnancy and birth outcomes. BMC Infect Dis 2018; 18 ...
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in persons at increased risk for influenza complications (see Table 1). Updated information on influenza activity and antiviral resistance is available from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8   doi:10.58347/tml.2024.1717a |  Show IntroductionHide Introduction

Sunscreens

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025  (Issue 1731)
for? Antioxidants (Basel) 2023; 12:138. 18. L Rabinovich and V Kazlouskaya. Herbal sun protection agents: human ...
Excessive exposure to ultraviolet (UV) radiation can cause erythema, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. In 2021, the FDA proposed a rule that would require additional safety studies for some sunscreen active ingredients and mandate better UVA protection in sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102   doi:10.58347/tml.2025.1731a |  Show IntroductionHide Introduction

Drugs for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021  (Issue 1620)
with an increased risk of SARS-CoV-2 infection or development of severe COVID-19, but data are limited ...
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-8 |  Show IntroductionHide Introduction

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
Malfertheiner et al. Management of Helicobacter pylori infection–the Maastricht V/Florence consensus report ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 |  Show IntroductionHide Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024  (Issue 1693)
, TIA, or thromboembolism 2 V Vascular disease2 1 A Age 65-74 years 1 Sc Sex category (female) 1 TIA ...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8   doi:10.58347/tml.2024.1693a |  Show IntroductionHide Introduction

Antifungal Drugs

   
Treatment Guidelines from The Medical Letter • Aug 01, 2012  (Issue 120)
photosensitivity. Arch Dermatol 2010; 146:300. 12. V Hafner et al. Pharmacokinetics of sulfobutylether-beta ...
The drugs of choice for treatment of fungal infections are listed in the table that begins on page 62. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections are available online from the Infectious Diseases Society of America (www.idsociety.org).
Treat Guidel Med Lett. 2012 Aug;10(120):61-8 |  Show IntroductionHide Introduction

Drugs for Psoriatic Arthritis

   
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019  (Issue 1588)
. 36. V Strand et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic ...
Psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis. A recent review found that about 20% of patients with psoriasis have psoriatic arthritis. Updated guidelines for treatment of psoriatic arthritis have recently been published.
Med Lett Drugs Ther. 2019 Dec 30;61(1588):203-10 |  Show IntroductionHide Introduction

Drugs for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
and renal events in type 2 diabetes. N Engl J Med 2017; 377:644. 15. V Perkovic et al. Canagliflozin ...
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-84 |  Show IntroductionHide Introduction

Drugs for Thyroid Disorders

   
Treatment Guidelines from The Medical Letter • Aug 01, 2009  (Issue 84)
. J Clin Endocrinol Metab 2006; 91:2592. 7. V Panicker et al. Common variation in the DIO2 gene ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 |  Show IntroductionHide Introduction

Antiviral Drugs

   
Treatment Guidelines from The Medical Letter • Mar 01, 2013  (Issue 127)
The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed elsewhere.
Treat Guidel Med Lett. 2013 Mar;11(127):19-30 |  Show IntroductionHide Introduction